General Hospital Pula

Pula 52100

0 studies enrolling now · 11 studies all time

What they study most

ALK+ Advanced NSCLC, Advanced or Metastatic Solid Tumors, Cachexia; Cancer, Carcinoma, Non-Small-Cell Lung, Colitis, Ulcerative, Crohn Disease, Early Breast Cancer, Melanoma, Non Small Cell Lung Cancer, PD-L1-selected Solid Tumors, Relapsing Multiple Sclerosis

Studies at this site

• A Study to Evaluate the Safety and Pharmacokinetics of the Intravenous Fixed-Dose Combination (IV FDC) of Tiragolumab and Atezolizumab in Participants With Locally Advanced, Recurrent or Metastatic Solid Tumors — Completed
• A Study Evaluating the Efficacy and Safety of Adjuvant Giredestrant Compared With Physician's Choice of Adjuvant Endocrine Monotherapy in Participants With Estrogen Receptor-Positive, HER2-Negative Early Breast Cancer (lidERA Breast Cancer) — Running, not enrolling
• A Study of TAK-981 Given With Pembrolizumab in Participants With Select Advanced or Metastatic Solid Tumors — Completed
• A Study of Brigatinib Compared to Alectinib in Adults With Non-Small-Cell Lung Cancer — Completed
• Open-Label Extension and Safety Study for Participants With Crohn's Disease Previously Enrolled in the Etrolizumab Phase III Study GA29144 — Stopped early
• A Study to Evaluate the Efficacy and Safety of Anamorelin HCl for the Treatment of Malignancy Associated Weight Loss and Anorexia in Adult Patients With Advanced Non-Small Cell Lung Cancer (NSCLC) — Completed
• A Study of Ocrelizumab in Comparison With Interferon Beta-1a (Rebif) in Participants With Relapsing Multiple Sclerosis — Completed
• A Study to Assess Whether Etrolizumab is a Safe and Efficacious Treatment for Participants With Moderately to Severely Active Crohn's Disease — Completed
• An Efficacy and Safety Study of Vedolizumab Intravenous (IV) Compared to Adalimumab Subcutaneous (SC) in Participants With Ulcerative Colitis — Completed
• Phase III Trial BI 695502 Plus Chemotherapy vs. Avastin® Plus Chemotherapy in Patients With Lung Cancer — Completed
• A Study of Vemurafenib Adjuvant Therapy in Participants With Surgically Resected Cutaneous BRAF-Mutant Melanoma — Completed